VSPharmTech
VSPharmTech is a Healthcare & Life Sciences startup based in South Korea, most recent round Series B, 1 tracked investor.
About VSPharmTech
VSPharmTech is a company headquartered in South Korea. Its most recent tracked round is Series B. Brouky classifies it under Healthcare & Life Sciences. Brouky records 1 investor associated with the company.
VSPharmTech develops small-molecule radiation sensitizer drugs that enhance the efficacy of anticancer treatments, focusing on low-toxicity radiosensitizers to improve chemotherapy and radiotherapy outcomes. Their lead product VS-101 has received FDA approval for phase 2 clinical trials targeting breast cancer and head and neck cancer.
Explore VSPharmTech's full profile on Brouky
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.